Dynatronics Corp (DYNT)

$0.17

+0.01

(+3.12%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Dynatronics Corp

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 9.35M → 7.65M (in $), with an average decrease of 9.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -1.01M → -667.72K (in $), with an average increase of 51.5% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 46.6% return, outperforming this stock by 125.8%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 76.8% return, outperforming this stock by 174.1%

Performance

  • $0.16
    $0.18
    $0.17
    downward going graph

    5.88%

    Downside

    Day's Volatility :11.11%

    Upside

    5.56%

    downward going graph
  • $0.17
    $0.91
    $0.17
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :81.32%

    Upside

    81.32%

    downward going graph

Returns

PeriodDynatronics CorpIndex (Russel 2000)
3 Months
-59.05%
0.0%
6 Months
-71.92%
0.0%
1 Year
-79.21%
0.0%
3 Years
-97.31%
-22.5%

Highlights

Market Capitalization
1.3M
Book Value
$1.41
Earnings Per Share (EPS)
-1.21
PEG Ratio
0.0
Wall Street Target Price
4.0
Profit Margin
-13.07%
Operating Margin TTM
-7.47%
Return On Assets TTM
-8.31%
Return On Equity TTM
-25.78%
Revenue TTM
33.6M
Revenue Per Share TTM
7.59
Quarterly Revenue Growth YOY
-17.1%
Gross Profit TTM
10.2M
EBITDA
-2.7M
Diluted Eps TTM
-1.21
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.92
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.26

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Dynatronics Corp(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 2252.94%

Current $0.17
Target $4.00

Company Financials

FY18Y/Y Change
Revenue
64.4M
↑ 80.14%
Net Income
-1.6M
↓ 14.15%
Net Profit Margin
-2.49%
↑ 2.73%
FY19Y/Y Change
Revenue
62.6M
↓ 2.87%
Net Income
-921.0K
↓ 42.52%
Net Profit Margin
-1.47%
↑ 1.02%
FY20Y/Y Change
Revenue
53.4M
↓ 14.63%
Net Income
-3.4M
↑ 271.88%
Net Profit Margin
-6.41%
↓ 4.94%
FY21Y/Y Change
Revenue
47.8M
↓ 10.5%
Net Income
2.0M
↓ 158.43%
Net Profit Margin
4.19%
↑ 10.6%
FY22Y/Y Change
Revenue
44.3M
↓ 7.24%
Net Income
-3.2M
↓ 261.35%
Net Profit Margin
-7.28%
↓ 11.47%
FY23Y/Y Change
Revenue
40.6M
↓ 8.41%
Net Income
-5.0M
↑ 54.01%
Net Profit Margin
-12.25%
↓ 4.97%
Q4 FY22Q/Q Change
Revenue
10.9M
↓ 9.71%
Net Income
-840.9K
↑ 56.63%
Net Profit Margin
-7.73%
↓ 3.28%
Q1 FY23Q/Q Change
Revenue
9.2M
↓ 15.14%
Net Income
-1.2M
↑ 48.3%
Net Profit Margin
-13.5%
↓ 5.77%
Q2 FY23Q/Q Change
Revenue
8.4M
↓ 8.63%
Net Income
-2.4M
↑ 90.94%
Net Profit Margin
-28.22%
↓ 14.72%
Q3 FY23Q/Q Change
Revenue
9.4M
↑ 10.83%
Net Income
-528.0K
↓ 77.82%
Net Profit Margin
-5.65%
↑ 22.57%
Q4 FY23Q/Q Change
Revenue
8.2M
↓ 12.84%
Net Income
-1.0M
↑ 91.56%
Net Profit Margin
-12.41%
↓ 6.76%
Q1 FY24Q/Q Change
Revenue
7.7M
↓ 6.05%
Net Income
-667.7K
↓ 33.98%
Net Profit Margin
-8.72%
↑ 3.69%
FY18Y/Y Change
Total Assets
42.1M
↑ 61.35%
Total Liabilities
20.7M
↑ 50.49%
FY19Y/Y Change
Total Assets
39.6M
↓ 5.76%
Total Liabilities
18.9M
↓ 8.71%
FY20Y/Y Change
Total Assets
27.6M
↓ 30.42%
Total Liabilities
7.7M
↓ 59.32%
FY21Y/Y Change
Total Assets
39.1M
↑ 41.94%
Total Liabilities
13.6M
↑ 77.44%
FY22Y/Y Change
Total Assets
35.4M
↓ 9.47%
Total Liabilities
13.7M
↑ 0.8%
FY23Y/Y Change
Total Assets
30.1M
↓ 15.16%
Total Liabilities
13.2M
↓ 3.85%
Q4 FY22Q/Q Change
Total Assets
35.0M
↑ 0.01%
Total Liabilities
14.5M
↑ 5.97%
Q1 FY23Q/Q Change
Total Assets
33.4M
↓ 4.42%
Total Liabilities
14.2M
↓ 2.23%
Q2 FY23Q/Q Change
Total Assets
30.1M
↓ 10.1%
Total Liabilities
13.2M
↓ 7.16%
Q3 FY23Q/Q Change
Total Assets
30.3M
↑ 0.94%
Total Liabilities
13.8M
↑ 4.51%
Q4 FY23Q/Q Change
Total Assets
29.3M
↓ 3.45%
Total Liabilities
13.8M
↓ 0.24%
Q1 FY24Q/Q Change
Total Assets
27.8M
↓ 5.24%
Total Liabilities
12.9M
↓ 6.17%
FY18Y/Y Change
Operating Cash Flow
761.8K
↓ 149.85%
Investing Cash Flow
-9.3M
↑ 1.0%
Financing Cash Flow
10.0M
↓ 0.45%
FY19Y/Y Change
Operating Cash Flow
325.7K
↓ 57.25%
Investing Cash Flow
-224.1K
↓ 97.59%
Financing Cash Flow
-1.5M
↓ 115.46%
FY20Y/Y Change
Operating Cash Flow
3.1M
↑ 848.71%
Investing Cash Flow
-292.4K
↑ 30.45%
Financing Cash Flow
-737.1K
↓ 52.19%
FY21Y/Y Change
Operating Cash Flow
383.0K
↓ 87.6%
Investing Cash Flow
1.5M
↓ 623.74%
Financing Cash Flow
2.0M
↓ 374.46%
FY22Y/Y Change
Operating Cash Flow
-4.9M
↓ 1375.2%
Investing Cash Flow
-317.8K
↓ 120.76%
Financing Cash Flow
-350.0K
↓ 117.3%
FY23Y/Y Change
Operating Cash Flow
372.0K
↓ 107.62%
Investing Cash Flow
-186.9K
↓ 41.21%
Financing Cash Flow
-332.7K
↓ 4.94%
Q4 FY22Q/Q Change
Operating Cash Flow
-72.6K
↓ 119.93%
Investing Cash Flow
-106.7K
↑ 439.2%
Financing Cash Flow
-90.1K
↓ 1.0%
Q1 FY23Q/Q Change
Operating Cash Flow
112.6K
↓ 255.17%
Investing Cash Flow
-9.8K
↓ 90.84%
Financing Cash Flow
-77.9K
↓ 13.49%
Q2 FY23Q/Q Change
Operating Cash Flow
-33.0K
↓ 129.3%
Investing Cash Flow
-9.8K
↑ 0.0%
Financing Cash Flow
-74.0K
↓ 5.01%

Technicals Summary

Sell

Neutral

Buy

Dynatronics Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dynatronics Corp
Dynatronics Corp
-56.82%
-71.92%
-79.21%
-97.31%
-98.18%
Stryker Corporation
Stryker Corporation
-2.4%
8.05%
13.44%
27.62%
63.8%
Boston Scientific Corp.
Boston Scientific Corp.
-0.67%
28.28%
46.57%
76.8%
81.99%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
5.79%
25.42%
-0.27%
-13.09%
45.49%
Abbott Laboratories
Abbott Laboratories
-0.19%
-8.55%
-2.5%
-12.31%
24.14%
Medtronic Plc
Medtronic Plc
-5.06%
-10.7%
-10.85%
-39.1%
-21.34%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dynatronics Corp
Dynatronics Corp
NA
NA
0.0
-0.92
-0.26
-0.08
NA
1.41
Stryker Corporation
Stryker Corporation
38.47
38.47
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
64.8
64.8
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
40.02
40.02
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.2
32.2
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
27.92
27.92
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dynatronics Corp
Dynatronics Corp
Buy
$1.2M
-98.18%
NA
-13.07%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
63.8%
38.47
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$113.4B
81.99%
64.8
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$56.0B
45.49%
40.02
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$179.3B
24.14%
32.2
13.96%
Medtronic Plc
Medtronic Plc
Buy
$98.8B
-21.34%
27.92
11.36%

Institutional Holdings

  • Renaissance Technologies Corp

    2.54%
  • Albion Financial Group (Utah)

    0.34%
  • Vanguard Group Inc

    0.30%
  • Tower Research Capital LLC

    0.08%
  • BlackRock Inc

    0.06%
  • Sunbelt Securities

    0.01%

Company Information

dynatronics manufactures, markets, and distributes advanced-technology medical devices, treatment tables, and rehabilitation - acute-care - sport medicine - chiropractic - massage equipment as well as over 8,000 products and supplies. in addition, dynatronics has the most experienced and knowledgeable sales force in the industry. with more than 60 sales representatives and 150 active distributors located throughout the country, we are able to provide immediate service. dynatronics has built a solid reputation over the past 31 years for competitive pricing, excellent customer service, and unmatched clinical support. our field support team handles everything from equipment set-up to in-service training.

Organization
Dynatronics Corp
Employees
154
CEO
Mr. Brian D. Baker
Industry
Health Technology

FAQs